TY - JOUR
T1 - Long-term secondary care costs of endometrial cancer
T2 - A prospective cohort study nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
AU - Pennington, Mark
AU - Gentry-Maharaj, Aleksandra
AU - Karpinskyj, Chloe
AU - Miners, Alec
AU - Taylor, Julie
AU - Manchanda, Ranjit
AU - Iyer, Rema
AU - Griffin, Michelle
AU - Ryan, Andy
AU - Jacobs, Ian
AU - Menon, Usha
AU - Legood, Rosa
PY - 2016/11
Y1 - 2016/11
N2 - Background: There is limited evidence on the costs of Endometrial Cancer (EC) by stage of disease. We estimated the long-term secondary care costs of EC according to stage at diagnosis in an English population-based cohort. Methods: Women participating in UKCTOCS and diagnosed with EC following enrolment (2001-2005) and prior to 31st Dec 2009 were identified to have EC through multiple sources. Survival was calculated through data linkage to death registry. Costs estimates were derived from hospital records accessed from Hospital Episode Statistics (HES) with additional patient level covariates derived from case notes and patient questionnaires. Missing and censored data was imputed using Multiple Imputation. Regression analysis of cost and survival was undertaken. Results: 491 of 641 women with EC were included. Five year total costs were strongly dependent on stage, ranging from £9,475 (diagnosis at stage IA/IB) to £26,080 (diagnosis at stage III). Stage, grade and BMI were the strongest predictors of costs. The majority of costs for stage I/II EC were incurred in the first six months after diagnosis while for stage III / IV considerable costs accrued after the first six months. Conclusions: In addition to survival advantages, there are significant cost savings if patients with EC are detected earlier.
AB - Background: There is limited evidence on the costs of Endometrial Cancer (EC) by stage of disease. We estimated the long-term secondary care costs of EC according to stage at diagnosis in an English population-based cohort. Methods: Women participating in UKCTOCS and diagnosed with EC following enrolment (2001-2005) and prior to 31st Dec 2009 were identified to have EC through multiple sources. Survival was calculated through data linkage to death registry. Costs estimates were derived from hospital records accessed from Hospital Episode Statistics (HES) with additional patient level covariates derived from case notes and patient questionnaires. Missing and censored data was imputed using Multiple Imputation. Regression analysis of cost and survival was undertaken. Results: 491 of 641 women with EC were included. Five year total costs were strongly dependent on stage, ranging from £9,475 (diagnosis at stage IA/IB) to £26,080 (diagnosis at stage III). Stage, grade and BMI were the strongest predictors of costs. The majority of costs for stage I/II EC were incurred in the first six months after diagnosis while for stage III / IV considerable costs accrued after the first six months. Conclusions: In addition to survival advantages, there are significant cost savings if patients with EC are detected earlier.
UR - http://www.scopus.com/inward/record.url?scp=84994417812&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0165539
DO - 10.1371/journal.pone.0165539
M3 - Article
AN - SCOPUS:84994417812
SN - 1932-6203
VL - 11
SP - 1
EP - 13
JO - PL o S One
JF - PL o S One
IS - 11
M1 - e0165539
ER -
